In This Section
Recent Events

View all events

Nizatidine

For the treatment of the following diseases where reduction of gastric acid is indicated:

  • Duodenal ulcer.
  • Benign gastric ulcer.
  • Prevention of duodenal or benign gastric ulcer recurrence.
  • Gastric oesophageal reflux disease (including erosions, ulcerations and associated heartburn).
  • Gastric and/or duodenal ulcer associated with concomitant use of non-steroidal anti-inflammatory drugs.

Summary of Product's Characteristics (SPC)

Please click here for the UK SPC details

Please click here for the Irish SPC details

Nizatidine
Product type:

H2 antagonist


Availability:

Prescription Only (POM)


Available as:
Capsule:

150mg, 300mg

Call us on
+44 (0)1438 727 822
Email Us
medinfo@flynnpharma.com
Enquire Online
Thank you for letting us use cookies to improve your experience. For more information on the cookies we use see our privacy policy.